Drug Development.

Area of Science:

• Neuroscience
• Molecular Biology
• Endocrinology

Background:

• Alzheimer's disease (AD) involves neuroinflammation and mitochondrial dysfunction, exacerbated by amyloid beta (Aβ).
• Loss of estradiol (E2) during aging and menopause correlates with increased AD risk.
• E2 exhibits neuroprotective properties by regulating mitochondrial function and inflammation.

Purpose of the Study:

• Investigate the neuroprotective effects of 17-beta estradiol (E2) against Aβ-induced neuroinflammation and mitochondrial dysfunction in Alzheimer's disease.
• Explore E2 as a potential therapeutic intervention for AD.

Main Methods:

• Primary cortical neurons were cultured and treated with Aβ to induce AD pathology, with some groups receiving E2 pretreatment.
• Western blotting, MTT, LDH, ELISA, and Seahorse XF assays were used to assess protein expression, cell viability, cytotoxicity, inflammatory markers, and mitochondrial function.
• NF-κB activation and levels of metabolic regulators like pAMPK and PGC-1α were analyzed.

Main Results:

• Aβ treatment decreased pAMPK and PGC-1α levels, impaired mitochondrial function, and activated pro-inflammatory NF-κB.
• E2 pretreatment restored pAMPK and PGC-1α levels, preserved mitochondrial function and ATP production, and reduced NF-κB activation.
• E2 attenuated Aβ-induced neurotoxicity and decreased inflammatory cytokine levels.

Conclusions:

• E2 demonstrates significant neuroprotective effects against Aβ in primary cortical neurons.
• E2 mitigates Aβ-induced mitochondrial dysfunction, inflammation, and neurotoxicity.
• E2 holds potential as a therapeutic agent for Alzheimer's disease by targeting mitochondrial dysfunction and neuroinflammation.